Who is sponsoring NCT01185171?

NCT01185171 is sponsored by University of Chicago.

What condition does NCT01185171 study?

NCT01185171 studies Head and Neck Cancer.

What is the status of NCT01185171?

NCT01185171 is currently COMPLETED.

Last reviewed 2023-05-09 · How we verify

Ph II Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer

NCT01185171 Phase 2 COMPLETED Results posted

The purpose of this study is to explore the activity of ZD1839 added to concurrent chemoradiotherapy and as adjuvant monotherapy in patients with locally advanced head and neck cancer. Activity is described in terms of response rate (complete responses only).

Details

Lead sponsor	University of Chicago
Phase	Phase 2
Status	COMPLETED
Enrolment	70
Start date	2003-01-27
Completion	2018-08

Conditions

Head and Neck Cancer

Interventions

ZD 1839 500mg

Primary outcomes

Complete Response Rate Achieved 1 Month After Concurrent Chemotherapy and Radiation Treatment — 1 month
To explore the activity of ZD1839 added to concurrent chemoradiotherapy and as adjuvant monotherapy in patients with locally advanced head and neck cancer. Activity is described in terms of response rate (complete responses only).

Countries

United States